The BRIGHT trial is a phase 1, open-label, dose-escalation study for CRISPR/Cas13-RNA targeting therapy for the treatment of ...

Practice-changing studies in dry age-related macular degeneration (AMD) and promising new directions in wet AMD, presented at ...

Study points to approach to improving anti-VEGF therapy for all wet AMD patients, and help subset of patients who lose vision ...

Dr Arshad Khanani shares insights, including data on anti-VEGF treatment and macular atrophy, fibrosis biomarkers, and PCV combination therapies.

Opens in a new tab or window A novel gene therapy (ABBV-RGX-314) was well tolerated and reduced treatment burden in patients with bilateral neovascular age-related macular degeneration (AMD ...

Reduced well-being and loss of productivity were contributors to the high economic burden in patients with late-stage age-related macular degeneration (AMD) living in the US, Germany, and Bulgaria.

A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that ...

A study from researchers at Wilmer Eye Institute, Johns Hopkins Medicine explains not only why some patients with wet ...

LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024- Appointed Jason Mitchell as chief ...

HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company, announced that the U.S. FDA has cleared its investigational new drug (IND) application for HG202, the world's first ...

If you're planning to upgrade your rig, now is the ideal time to look for the best AMD processor for your needs and budget. With Black Friday deals approaching, you can find some fantastic deals ...